Step Into a World of Imagination With The Newly-Renovated Thematic Rooms at Four Points Surabaya, Pakuwon Indah
SURABAYA, Indonesia, June 16, 2025 /PRNewswire/ -- Four Points by Sheraton Surabaya, Pakuwon Indah proudly announces the launch of its newly renovated thematic rooms, offering guests especially families with young children an extraordinary staycation experience filled with imagination, wonder, and lots of fun.
The new addition features six uniquely designed rooms, where each of the room designed to delight the little guests' fantasy to life through carefully curated interiors, interactive design elements, and playful atmospheres that spark joy and creativity. Whether it's a magical escape or an adventurous journey, these rooms are built to inspire unforgettable memories.
Introducing the Six Thematic Rooms:
Strategically located above the Pakuwon Mall, the largest shopping mall in Indonesia, Four Points by Sheraton Surabaya, Pakuwon Indah provides the perfect balance of leisure and convenience, moreover enhanced by these imaginative new room options. For reservations and more information, visit https://www.marriott.com/subfk or contact at +6231.297.10000
Press Contact
Ms. Cindy Yuwono
Complex Marketing Communications Manager
[email protected]
About Four Points by Sheraton®
Four Points by Sheraton is a global brand with over 335 hotels in over 45 countries and territories. At Four Points, travel is reinvented where timeless classics are woven with modern details, paired with genuine service in a casual environment—all around the world. Four Points hotels can be found in the heart of urban centers, near the beach, by the airport, or in the suburbs. Each hotel offers a familiar place to kick back and relax with an authentic sense of the local, where guests can watch sports and enjoy the brand's Best Brews® program. Four Points is proud to participate in Marriott Bonvoy®, the global travel program from Marriott International. The program offers members an extraordinary portfolio of global brands, exclusive experiences on Marriott Bonvoy Moments and unparalleled benefits including free nights and Elite status recognition. To enroll for free or for more information about the program, visit marriottbonvoy.com. To learn more about Four Points, visit us online.
View original content to download multimedia: https://www.prnewswire.com/apac/news-releases/step-into-a-world-of-imagination-with-the-newly-renovated-thematic-rooms-at-four-points-surabaya-pakuwon-indah-302482297.html
SOURCE Four Points by Sheraton Surabaya, Pakuwon Indah
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Terra Metals secures investment to fund Dante project in Australia
Terra Metals has secured financial commitments of A$4m ($2.6m) from strategic investors through the issuance of 114.2 million new ordinary shares at A$0.035 each. The proceeds will support the exploration and development of the company's wholly owned Dante copper-gold-platinum group metal project in Western Australia (WA). The strategic investors include Golden Energy and Resources (GEAR), an Asia-Pacific resources company, and Matthew Latimore, a notable figure in the Australian resources sector. GEAR operates through various coal and gold mining subsidiaries including Stanmore Resources and Illawarra Coal Holdings. GEAR executive director and chief investment officer Mark Zhou said: 'The Dante Project is clearly a standout district-scale opportunity for a globally significant critical minerals resource. GEAR is pleased to take up a shareholding in Terra Metals and to be partnering with and supporting Terra Metals in this exploration journey.' Latimore, founder and president of M Resources, holds stakes in several resource companies. Latimore said: 'This investment is aligned with M Group's long-term growth strategy in minerals essential to the energy transition and future economy. It also complements our existing Queensland-based vanadium and graphite assets held through M Critical Minerals.' Terra Metals' largest shareholder, Tribeca Investment Partners, has also pledged to maintain its 15% stake under the placement, subject to shareholder approval. The proceeds from the placement will be used for drilling activities and general corporate purposes. The placement will be completed in two tranches, with the second contingent on shareholder approval at an upcoming General Meeting. Terra Metals has already conducted more than 17,000m of drilling, revealing a laterally extensive reef-style system with potential across hundreds of kilometres. An independent South African resource consultancy is scheduled to visit the site in mid-June in preparation for the company's maiden mineral resource estimate. In January 2025, Terra Metals announced an option to acquire HRM Exploration, which holds four exploration licences covering 618km², contiguous with the Dante project. "Terra Metals secures investment to fund Dante project in Australia" was originally created and published by Mining Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
34 minutes ago
- Bloomberg
Abu Dhabi's Huge Energy Deal Boosts Ambitions to Shape Gas Giant
Abu Dhabi is boosting its ambitions to build a top liquefied natural gas producer with its biggest energy deal, as the petrostate targets a market it sees as key to its economic growth. The $19 billion offer for Australia's Santos Ltd. by the investment unit of government-owned Abu Dhabi National Oil Co. would give access to production and export of LNG feeding straight into fast-growing Asian markets. The unit — XRG PJSC — would add Santos to a tally of gas and chemicals deals on the US Gulf Coast, Africa, the Middle East and Europe.
Forbes
an hour ago
- Forbes
What's Happening With Boston Scientific Stock?
CHONGQING, CHINA - APRIL 20: In this photo illustration, the logo of Boston Scientific Corporation ... More is displayed on a smartphone screen, with the company's branding and slogan Advancing science for life in the background, representing the American biomedical and biotechnology engineering firm known for developing medical devices used in interventional medical specialties, on April 20, 2025, in Chongqing, China. (Photo by) Boston Scientific (NYSE:BSX) has experienced a stock price increase of over 30% in the last twelve months, greatly exceeding the S&P 500's gain of 9%. This remarkable performance can be credited to the launch of new products, which have enhanced sales growth and widened profit margins. Nonetheless, the pivotal question for investors is whether the BSX stock, currently priced at around $100, offers a worthwhile buying opportunity. We believe that at its current valuation, Boston Scientific seems relatively overpriced, especially when compared to the broader market and its historical performance metrics. That being said, if you are looking for potential upside with less volatility than individual stocks, the Trefis High-Quality portfolio serves as an option – having outperformed the S&P 500 and yielding returns of over 91% since its inception. Additionally, take a look at – Will Adobe Stock See Higher Levels? When examining Boston Scientific's valuation in relation to the S&P 500, the stock appears quite pricey across essential metrics. The company's price-to-sales (P/S) ratio is at 8.3, notably greater than the S&P 500's 3.0. Likewise, its price-to-free cash flow (P/FCF) ratio of 38.0 significantly surpasses the benchmark's 20.5. Moreover, Boston Scientific's price-to-earnings (P/E) ratio stands at a notable 71.4, as opposed to the S&P 500's 26.4. These numbers collectively suggest that investors are paying a considerable premium for Boston Scientific's sales, profits, and cash flow relative to the overall market. Check out – Boston Scientific's Valuation Ratios – for further insights. Boston Scientific has shown significant revenue growth in recent years. Over the past three years, its revenues have increased at an average rate of 13.1%, dramatically outpacing the S&P 500's rise of 5.5%. More recently, Boston Scientific's revenues increased by 19.4% over the past twelve months, climbing from $15 billion to $18 billion. In its latest quarter, quarterly revenues experienced a solid rise of 20.9%, growing from $3.9 billion to $4.7 billion compared to the previous year. These figures highlight the company's robust operational momentum in driving sales. The company's profit margins typically reside around the average for firms within the Trefis coverage universe. Over the past four quarters, Boston Scientific's operating income totaled $3.2 billion, yielding a solid operating margin of 18.5%, which exceeds the S&P 500's 13.2%. Boston Scientific's Operating Cash Flow (OCF) for the same period was $3.8 billion, reflecting a good OCF margin of 21.7%, compared to the S&P 500's 14.9%. Boston Scientific's Net Income over the last four quarters was $2.0 billion, resulting in a moderate net income margin of 11.6%, which aligns with the average of the S&P 500. Boston Scientific's balance sheet appears to be moderate. As of the latest quarter, the company's debt was $12 billion, in contrast to a significant market capitalization of $147 billion (as of June 13, 2025). This results in a strong Debt-to-Equity Ratio of 8.1%, which is substantially lower and more favorable than the S&P 500's 19.9%. However, a slight concern arises from its cash position; cash and cash equivalents totaling $725 million yield a suboptimal Cash-to-Assets Ratio of 1.8% compared to total assets of $40 billion, and significantly lower than the S&P 500's 13.8%. Boston Scientific's stock has exhibited mixed performance during previous market downturns, sometimes performing worse than the S&P 500. During the "Inflation Shock" of 2022, BSX stock faced a decline of 25.2%, closely mirroring the S&P 500's decrease of 25.4%, but fully recovered by December 2022. The COVID-19 pandemic in 2020 had a more severe impact, causing BSX stock to drop 43.5% in contrast to a 33.9% fall for the S&P 500; however, it regained its value by August 2021. The Global Financial Crisis of 2008 posed the most significant challenge, with BSX stock plunging 70.5% compared to the S&P 500's decline of 56.8%, and it took until November 2015 for the stock to completely recover. In conclusion, Boston Scientific demonstrates 'Extremely Strong' growth, 'Strong' profitability, and a 'Neutral' financial stability profile. Nevertheless, its 'Weak' resilience during downturns and, particularly, its 'Very High' valuation contribute to an 'Overall Neutral' evaluation. The current price-to-sales ratio of 8.3x is significantly higher than Boston Scientific's historical average of 5.9x, indicating that the stock is currently trading at a substantial premium. Although Boston Scientific's improving sales growth and profitability are encouraging factors that may continue attracting investor interest, the high valuation at this time poses an increased risk. For investors looking for upside with reduced volatility relative to individual stocks, portfolios such as the Trefis High Quality (HQ) portfolio and Reinforced Value (RV) Portfolio provide alternatives. The HQ Portfolio, focusing on risk assessment and consisting of 30 stocks, has a proven history of outperforming the S&P 500 over the last four years, yielding superior returns with less risk. Similarly, the RV Portfolio, which is rebalanced quarterly with a mix of large, mid, and small-cap stocks, has outperformed its all-cap stocks benchmark.
